{"id":"W3088566771","doi":"10.1016/j.annonc.2020.08.1260","title":"1137P Incidence and time course of adverse events (AEs) with atezolizumab (A) in combination with vemurafenib (V) and cobimetinib (C) in the phase III IMspire150 study","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"Roche (Canada)","funders":"F. Hoffmann-La Roche","keywords":"Medicine; Rash; Internal medicine; Gastroenterology; Adverse effect; Diarrhea; Incidence (geometry); Population; Asymptomatic; Placebo; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00121181,0.0004161326,0.000976215,0.0001682145,0.0001498891,0.000580035,0.0002494215,0.0005219491,0.002363779],"category_scores_gemma":[0.001015963,0.0002595076,0.001663829,0.0003157583,0.0001678797,0.0003539597,0.000196282,0.001464587,0.000371071],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003250451,"about_ca_system_score_gemma":0.0003223461,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005141108,"about_ca_topic_score_gemma":0.001254213,"domain_scores_codex":[0.9995676,0.0001668117,0.00003533881,0.00008838109,0.00007129042,0.00007057613],"domain_scores_gemma":[0.999395,0.0002098846,0.0002044763,0.00004113683,0.00005080515,0.00009873437],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6025127,0.003070806,0.1686393,0.001457372,0.01276405,0.0009585708,0.0001216657,0.006911735,0.04655882,0.0005420509,0.01032972,0.1461333],"study_design_scores_gemma":[0.05957231,0.1224553,0.7783403,0.0001499199,0.008797954,0.002286966,0.0001590578,0.007017328,0.007509814,0.0007980607,0.01279814,0.0001147932],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9900824,0.003823423,0.0005222086,0.0001730712,0.00007774506,0.0001013106,0.002561927,0.00005464146,0.002603244],"genre_scores_gemma":[0.9950782,0.0007908684,0.0002481723,0.0001691841,0.00004693186,0.00009777634,0.002271547,0.00001446187,0.001282735],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002363779,"threshold_uncertainty_score":0.007907629,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03152753028955441,"score_gpt":0.331205111221538,"score_spread":0.2996775809319836,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}